Sat, May 10, 2025
Fri, May 9, 2025
Thu, May 8, 2025
Wed, May 7, 2025
Tue, May 6, 2025
Mon, May 5, 2025
Sun, May 4, 2025
Sat, May 3, 2025
Fri, May 2, 2025
Thu, May 1, 2025
Wed, April 30, 2025
Tue, April 29, 2025
Mon, April 28, 2025
Sun, April 27, 2025
Sat, April 26, 2025
Fri, April 25, 2025
Thu, April 24, 2025
Wed, April 23, 2025
Tue, April 22, 2025
Mon, April 21, 2025
Sun, April 20, 2025
[ Sun, Apr 20th ] - BBC
The Video Playlist
Sat, April 19, 2025
Fri, April 18, 2025

Gilead Sciences Stock Falls as Slumping COVID-19, Cancer Drug Sales Hit Revenue


//science-technology.news-articles.net/content/2 .. ping-covid-19-cancer-drug-sales-hit-revenue.html
Published in Science and Technology on by Investopedia   Print publication without navigation

Gilead Sciences missed first-quarter revenue estimates as sales of its COVID-19 and cancer drugs declined.

Gilead Sciences experienced a significant drop in its stock price, falling over 10% after reporting a 4% year-over-year revenue decline to $6.6 billion in the third quarter, primarily due to decreased sales of its COVID-19 treatment, Veklury, and cancer drug, Yescarta. The company's oncology division saw a 26% revenue drop, attributed to reduced demand for Yescarta and challenges in the launch of Trodelvy. Despite these setbacks, Gilead's HIV treatment segment showed growth, with a 4% increase in sales, driven by demand for Biktarvy. The company also revised its full-year revenue guidance downwards, now expecting between $26.7 billion and $26.9 billion, reflecting the ongoing impact of lower Veklury sales. Additionally, Gilead announced a $3 billion share repurchase program to return value to shareholders amidst these challenges.

Read the Full Investopedia Article at:
[ https://www.investopedia.com/gilead-sciences-stock-falls-as-slumping-covid-19-cancer-drug-sales-hit-revenue-11721926 ]

Publication Contributing Sources